Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Impact of BRCA1/2 mutations status on patient reported outcomes in HER2- advanced breast cancer: Results from a multi-country real-world study


03 May 2019


Poster lunch


Alex Rider


Annals of Oncology (2019) 30 (suppl_3): iii47-iii64. 10.1093/annonc/mdz100


A. Rider1, R.G..W. Quek2, K. Lewis3, J. Kemp1, A. Niyazov4

Author affiliations

  • 1 Oncology, Adelphi Real World, SK10 5JB - Bollington/GB
  • 2 Health Economics & Outcomes Research, Pfizer Inc., 94105 - San Francisco/US
  • 3 Oncology, Adelphi Real World, Bollington/GB
  • 4 Health Economics & Outcomes Research, Pfizer, New York/US



Limited information is available on the effect of BRCA1/2 mutations on patient reported outcomes (PROs). This multi-country study assesses the impact of BRCA1/2 mutation status on patient demographics, cancer-related and breast cancer specific PROs in women with human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).


Oncologists extracted data from patient charts in adult women with HER2- ABC across the US and the United Kingdom, Spain, Germany, France and Italy (EU5) via the Adelphi Advanced Breast Cancer Disease Specific Program in 2017. A subset of patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) and the breast cancer module QLQ-BR23. Patients were categorized into 2 mutually exclusive cohorts; BRCA1/2 mutations (BRCAm) and BRCA wild type (BRCAwt). Differences in patient demographics were compared using t-tests and Pearson’s Chi-squared tests. PROs were compared utilizing inverse probability weighted regression adjustment across multiple potential confounders.


Overall 199 patients participated; (BRCAm n = 37, BRCAwt n = 162). Patients with BRCAm were significantly younger (50.3 vs. 55.4 years old), [P = 0.018] and more likely have a family history of breast or ovarian cancer (43% vs. 22%), [P = 0.003] relative to BRCAwt. Significantly worse scores in role functioning (44.9 vs. 57.9), [P = 0.002] and dyspnea (47.7 vs. 37.0), [P = 0.012] were observed in patients with BRCAm relative to BRCAwt. No statistically significant differences in other EORTC PRO scales were observed.


In this study of adult women with HER2- ABC, patients with BRCAm were significantly younger and more likely to have a family history of breast or ovarian cancer than BRCAwt. Patients with BRCAm reported significantly worse role functioning and dyspnea suggesting that BRCAm targeted treatment options leading to PROs improvements in these patients are needed.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study





A. Niyazov: Employee, stockholder: Pfizer. R.G.W. Quek: Employee: Pfizer Inc.; Stock ownership: Pfizer Inc., Amgen Inc. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings